Trust Co. of Vermont Purchases Shares of 12,339 Gilead Sciences, Inc. $GILD

Trust Co. of Vermont acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,339 shares of the biopharmaceutical company’s stock, valued at approximately $1,559,000.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter worth about $2,617,152,000. Boston Partners acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $398,905,000. Bank of America Corp DE boosted its position in Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 3.3%

Shares of GILD stock opened at $143.44 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a 50 day simple moving average of $130.69 and a 200-day simple moving average of $136.46.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,000 shares of company stock worth $10,837,860 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GILD. Morgan Stanley cut their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Barclays dropped their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $158.04.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: A federal appeals court blocked companies from importing and selling cheaper foreign versions of Biktarvy in the United States. The ruling helps protect revenue from Gilead’s leading HIV treatment and removes a potential competitive and pricing threat. Gilead stock court ruling on Biktarvy imports
• Positive Sentiment: Gilead’s HIV franchise remains the primary growth engine. Biktarvy continues to lead treatment, while the newer Yeztugo product and additional pipeline programs could expand the company’s prevention and treatment opportunities. Is Gilead’s Expanding HIV Portfolio a Growth Catalyst?
• Positive Sentiment: Commentary from The Motley Fool highlighted Gilead as an underappreciated healthcare turnaround story, citing double-digit quarterly revenue growth, strong HIV sales, acquisitions, and an expanding oncology portfolio. This supports investor optimism about longer-term diversification beyond HIV. Gilead Sciences turnaround story
• Neutral Sentiment: Gilead is participating in a highly competitive antibody-drug conjugate oncology market. The company’s technology and patent position may create future opportunities, but the landscape also involves substantial competition and development risk. Cancer and antibody-drug conjugates patent landscape
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares worth approximately $3.85 million. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal about management’s outlook, though insider selling can still weigh modestly on sentiment.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.